Liquidia Technologies, Inc. Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Morrisville NC United States (2004)
Status: No NME R&D (2004)

Organization Overview

First Clinical Trial
2010
NCT01224262
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Liquidia Technologies, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

treprostinil (remodulin) (3 trials)

Drugs in Phase 2 Trials (2)

inactivated influenza vaccine (1 trial)

liq001 (1 trial)

Drugs in Phase 1 Trials (1)

levobupivacaine (chirocaine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 1)

Familial Primary Pulmonary Hypertension (Phase 3)

Hypertension (Phase 3)

Hypertension, Pulmonary (Phase 3)

Influenza, Human (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 4